Last reviewed · How we verify

Methoxyflurane - Penthrox

St. Paul's Hospital, Canada · Phase 3 active Small molecule

Methoxyflurane is a volatile halogenated anesthetic that provides rapid analgesia and sedation through central nervous system depression.

Methoxyflurane is a volatile halogenated anesthetic that provides rapid analgesia and sedation through central nervous system depression. Used for Acute pain relief in emergency departments and acute care settings, Trauma-related pain management, Procedural analgesia.

At a glance

Generic nameMethoxyflurane - Penthrox
SponsorSt. Paul's Hospital, Canada
Drug classVolatile halogenated anesthetic
TargetGABA receptors, NMDA receptors
ModalitySmall molecule
Therapeutic areaAcute Pain Management
PhasePhase 3

Mechanism of action

Methoxyflurane acts as a general anesthetic by enhancing inhibitory GABAergic neurotransmission and inhibiting excitatory glutamatergic signaling in the central nervous system. Penthrox is a low-dose formulation administered via inhalation that produces analgesia and mild sedation at sub-anesthetic concentrations, making it suitable for acute pain relief in emergency and acute care settings without requiring full anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: